Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Acknowledgements This work was supported
2021-10-22

Acknowledgements This work was supported by grants from the Agencia Nacional de Promoción Científica y Tecnológica (PICT2013-0495, PICT2016-1821), and from CONICET (PIP 2013-562), as well as from Fundación René Barón and Fundación Williams. Introduction Histamine poisoning, also known as scom
-
br Pharmacological anti aging approaches and the Hippo pathw
2021-10-22

Pharmacological anti-aging approaches and the Hippo pathway Aging and age-related pathologies are the main causes of disabilities and death. As Magalhañes and colleagues suggest, the challenges of developing anti-aging pharmacological therapies may, in part, be due to the complexity of aging mole
-
br Cholecystokinin CCK CCK is secreted by enteroendocrine I
2021-10-22

Cholecystokinin (CCK) CCK is secreted by enteroendocrine I-cells of the duodenum and jejunum in response to amino acids and lipids [14]. There are two forms of the CCK receptor, CCK1 which is expressed on pancreatic α- and β-cells while CCK2 is located on somatostatin-secreting δ-cells [8]. CCK r
-
Alvespimycin In summary through medicinal chemistry design a
2021-10-22

In summary, through medicinal chemistry design and computer-assisted conformational modeling, the initial lead was evolved into a series of dihydrobenzofuran derivatives, , as potent GPR119 agonists. Optimization of general structure at various regions of the molecule, including the substituent on
-
No other lacZ mutant showed a marked difference in
2021-10-22

No other lacZ mutant showed a marked difference in mutation rate between fpg and fpg backgrounds (that is, rates were comparable between HS101 and CSH1191, HS102 and CSH1192, etc.). The number of reversion mutants was much higher in HS1194 than in any other fpg strain. The inclusion of the pTRC99a
-
The unique mechanism of EAAT anion channel gating results in
2021-10-22

The unique mechanism of EAAT anion channel gating results in neuronal or glial anion conductances that follow changes in substrate concentrations and thus allow feedback control of glutamate release (Wersinger et al., 2006) or modification of GABAergic postsynaptic currents by glutamatergic signals
-
cysteine protease inhibitor br Methods GLUT DS was diagnosed
2021-10-22

Methods GLUT1DS was diagnosed either when analysis of the SLC2A1 gene showed a pathogenic mutation and/or when cerebrospinal fluid (CSF) analysis met the criteria for GLUT1DS: a CSF cysteine protease inhibitor below the 10th percentile, a cerebrospinal fluid (CSF) to blood ratio below the 25th p
-
Go 6983 br Introduction Maintaining blood glucose
2021-10-22

Introduction Maintaining blood glucose within an appropriate range is crucial for survival. In diabetes, those who suffer episodes of severe hypoglycemia have an increased risk of death [1], [2]. The Go 6983 is especially dependent on an adequate, continuous supply of circulating glucose to fuel
-
Further we examined the degradation of
2021-10-22

Further, we examined the degradation of Cx43. Autophagy and the proteasome system have previously been implicated in Cx43 degradation (Falk et al., 2014). DEX inhibited communication between Fmoc-Gln(Trt)-OH by promoting the degradation of Cx43 through autophagy in osteocytes (Gao et al., 2016). In
-
Until recently the mechanism of how GSMs shifted secretase c
2021-10-22

Until recently the mechanism of how GSMs shifted γ-secretase cleavage was poorly understood. Today, building on the sequential cleavage model developed by Ihara and colleagues [14], there is evidence that GSMs act as processivity enhancers, and iGSMs as inhibitors of processivity [120]. At least for
-
In the present study the relative mRNA expression
2021-10-22

In the present study, the relative mRNA ceritinib levels of CsLCCH3 and Cs8916 subunits in the egg were the highest, which were consistent with those of LsLCCH3 and Ls8916 from L. striatellus (Wei et al., 2017b) and were also similar to CsRDLs (Sheng et al., 2018; Meng et al., 2018). Overall, the t
-
The feasibility of using the Fas Fas ligand
2021-10-21

The feasibility of using the Fas/Fas ligand (FasL) system to target vascular progenitor Loxapine contributing to intimal hyperplasia has been shown in many studies [[18], [19], [20], [21], [22], [23], [24]]. Fas receptor, a member of tissue necrosis factor family, is a death receptor that initiates
-
Recent studies are beginning to explore this complex interpl
2021-10-21

Recent studies are beginning to explore this complex interplay of pathways. For example, intracellular trafficking of poly(lactic-co-glycolic acid)(PLGA) based nanoparticles was studied in detail using 30 different Rab proteins as markers for intracellular transport vesicles (involved in exocytosis,
-
The present study was designed to clarify the
2021-10-21

The present study was designed to clarify the distribution and the function of the endothelin receptors in the guinea-pig urinary bladder. We found that endothelin-1 produced a clear tonic contraction via both Isoniazid sale subtypes, the endothelin ETA and ETB receptor, and that sarafotoxin S6c al
-
l-ascorbic acid br Acknowledgments The breast cancer laborat
2021-10-21

Acknowledgments The breast cancer laboratory is supported by the Australian National Health and Medical Research Council (NHMRC) grants no. 1016701, no. 1024852, no. 1086727; NHMRC IRIISS; the Victorian State Government through VCA funding of the Victorian Breast Cancer Research Consortium and Op
16129 records 585/1076 page Previous Next First page 上5页 581582583584585 下5页 Last page